NCT02027298View on ClinicalTrials.gov

Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

November 30, 2013

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions

Primary Sjogren's SyndromeSecondary Sjogren's SyndromeInflammatory ArthritisRheumatoid Arthritis

Interventions

DRUG

Abatacept

by SC injection of 125 mg weekly for 6 months

Trial Locations (1)

44195

Cleveland Clinic, Cleveland

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

The Cleveland Clinic

OTHER

NCT02027298 - Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study | Biotech Hunter | Biotech Hunter